Group 1 - Company recently announced the commercialization of OC-01, a nasal spray product for increasing tear secretion in dry eye patients, marking it as the only approved product of its kind in China [1] - Dry eye disease is a common chronic ocular surface condition in China, with an estimated prevalence of 21%-30%, affecting approximately 360 million people [1] - The innovative nasal delivery method of OC-01 significantly improves natural tear secretion and is expected to enhance patient compliance due to its ease of use compared to traditional eye drops [1] Group 2 - Company has established a strategic focus on the ophthalmology field, developing a comprehensive portfolio of innovative drugs for various eye conditions, with multiple products expected to be approved in the next three years [2] - Recent FDA approval for DOORwaY90, a yttrium-90 microsphere injection, allows it to treat unresectable hepatocellular carcinoma (HCC) without size restrictions, making it the first product to receive such dual indications [2] - The international multi-center Phase III clinical trial for CBT-001, an innovative drug for treating pterygium, has successfully completed patient enrollment [2] Group 3 - On July 17, the company's stock rose by 5.13%, closing at HKD 9.83 per share, with a cumulative increase of over 64% from May 1 to July 17 [3]
远大医药治疗干眼症的全球首创鼻喷产品进入临床应用